Articles On Botanix Pharmaceuticals (ASX:BOT)

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by “selling” stocks you do not actually own in the hope of...

Clinical stage Australian-based cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it has a ne product opportunity for the treatment of papulopustular rosacea.

Introduction Investors seek high return on stocks and continue to invest in the stock market. Investors with higher risk-taking abilities are rewarded higher. However, in most of the cases, investors tend to lose their capital because of la...

‘Pot stocks’ were making headlines in 2018. California, one of the world’s biggest economies and the most populous state in the US, finally enacted legislation to legalise the recreational use of cannabis. It joined a growing list of US st...

Digital healthcare service has evolved as one of the fastest-growing industries in the modern era. Introduction of technology in medical science has emerged as one of the biggest blessings for human. Digitally connected network systems have...

The federal government has taken steps to cut red tape and speed up the granting of licences for Australia’s cannabis players. Health Minister Greg Hunt said the federal government would boost the nation’s medicinal cannabis industry by pri...

Opthea (ASX: OPT) shares have more than doubled this morning after announcing its Phase IIb clinical trial was a success. The 366-patient study tested its OPT-302 drug, which battles wet (neovascular) age-related macular degeneration (AMD)...

On the cusp of what Botanix (ASX: BOT) is calling "one of the most significant chapters" in the development of its cannabis portfolio, the company has completed a $40 million capital raising. The oversubscribed share placement was led by...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is sagging today after the company made two announcements to the ASX during a two-day trading halt. On Monday trading, BOT shares closed at 26 cents per share, but re-opened this morni...

Botanix Pharmaceuticals Limited (ASX: BOT) is an Australian-headquartered company, engaged in the development of next-gen therapeutics that are safe and effective for the treatment of serious skin diseases. It is a clinical stage cannabinoi...

Skin treatments company Botanix Pharmaceuticals is in front of investors seeking a $40 million equity injection on Tuesday. 

A new chain of medical cannabis clinics are set to roll out across Australia as part of a collaboration between Australian biopharma Zelda Therapeutics (ASX:ZLD) and Emerald Clinics. Zelda is developing a new cannabis-based treatment to red...

Taking the cannabis market to the next level, the US is now taking a closer look at the industry’s lack of access to financial services. Forbes reported on Tuesday that a Republican-controlled Senate committee had scheduled a hearing for ne...

The biotechnology sector is one of those sectors that presents an incredible opportunity for huge returns to investors. This is because the business of curing diseases can be lucrative, and any company with a small market capitalisation can...

Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced new data from studies recently conducted involving its cannabidiol antimicrobial platform and a new development program ‘AB 2367’.

The below-mentioned healthcare stocks have provided significant returns in the last six months and have come up with major updates today (i.e. 15th July 2019).  Let’s take a look at these updates. Rhinomed Limited (ASX: RNO) A Melbourne-ba...

Although it has fought back from its lows, the S&P/ASX 200 index is still on course to start the week on a disappointing note. At the time of writing the benchmark index is down 0.35% to 6,672.5 points. Four shares that have not let th...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has continued its impressive run and is up over 14% to 24 cents in morning trade. This means the clinical stage cannabinoid company’s shares have gained almost 250% since the start of...

Adherium (ASX: ADR) shares have risen 19 per cent this morning following news the asthma monitoring firm had received clearance to sell its devices in the US. The Food and Drug Administration (FDA) granted 510(k) clearance for its Hailie se...

As the cannabis sector gains momentum in Australia and given that medicinal cannabis was legalised in February 2016, at a federal level, various companies are rapidly advancing their clinical trials for relevant products to capitalise on th...

The Australian share market may have dropped off a touch this week, but that hasn’t stopped a number of shares from continuing their charge. Three shares that reached 52-week highs or better this week are listed below. Here’s why they have...

Do you know that market enthusiasts believe that legalising cannabis would generate approximately $8.5 billion in the country’s federal and state tax? Ponder over the massive revenue that this sector would add to the necessities related to...

I think it is fair to say that 2019 has been a very positive year for Australian investors. Since the turn of the year the All Ordinaries index has pushed a sizeable 20% higher. Whilst this means that the majority of local shares are recor...

Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced that Dr Mark Blaskovich presented antimicrobial data from studies recently conducted with its product candidate BTX 1801 at the American Society for...

The two ASX traded companies BOT and NHS  had updated investors about the latest developments in the market. With a positive YTD return, both stocks have gained momentum over the past few months. Botanix Pharmaceuticals Limited (ASX: BOT) S...

In another “world first” this week, Botanix Pharmaceuticals (ASX: BOT) has revealed its antimicrobial cannabidiol (CBD)-based product BTX 1801 can treat serious skin infections including superbugs. The study using BTX 1801 was carried out i...

In another “world first” this week, Botanix Pharmaceuticals (ASX: BOT) has revealed its antimicrobial cannabidiol (CBD)-based product BTX 1801 can treat serious skin infections including superbugs. The study using BTX 1801 was carried out i...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has been a standout performer on the Australian share market on Thursday. In morning trade the clinical stage cannabinoid company’s shares rocketed 25% higher to an all-time high of 17....

Pot stock Botanix (ASX:BOT) says one of its cannabis formulations kills superbugs — in animals and in the lab. Botanix is better known to investors as a biotech developing cannabis-based medications for skin conditions, but it also has a re...

At the start of every trading day, it can be useful to know which stocks are humming out of the gate. Often, the moves are part of the usual market ructions in small caps, but sometimes a big announcement can cause a stock to rocket higher...

Medical dermatology company Botanix Pharmaceuticals (ASX:BOT) has updated investors on the findings of the BTX 1801 antimicrobial study.

Shares in grow-your-own-bone biotech Orthocell (ASX:OCC) are up after it proved, once again, that we live in science fiction times. Today the company said all 10 patients in a dental bone regeneration study had successfully grown enough new...

The market has continued its charge on Wednesday and is trading notably higher this morning. Two companies that are certainly on a high right now are the cannabis companies listed below. Here’s why they are smoking the market today: The Bot...

New results from a “world-first” study by Botanix Pharmaceuticals (ASX: BOT) has identified significant anti-inflammatory and immune modulating effects from using cannabidiol (CBD) to treat skin diseases such as psoriasis. The medical derma...

Two stocks BOT and PM1 are on trading halts, pending their upcoming announcements on ASX. Let us have an overview of the recent developments and the performance of the stocks for these companies. Botanix Pharmaceuticals Limited Strong Devel...

Honey containing THC *might* be able to be exported and imported. The UK is the Next Big Thing in pot, Brexit or no. And 2020 is starting to look like a very hard deadline for a series of big events. There are 30 companies doing, or saying...

Honey containing THC *might* be able to be exported and imported. The UK is the Next Big Thing in pot, Brexit or no. And 2020 is starting to look like a very hard deadline for a series of big events. There are 30 companies doing, or saying...